26 Jan Full Year 2022 Trading Update
Posted at 07:00h in Board, Novacyt Group
Full year revenue and EBITDA in line with guidance
Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases
Paris, France and Eastleigh, UK – 26 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2022. Reported revenues and EBITDA for the period are both expected to be in line with guidance.